MEI Pharma, Inc.

271 articles with MEI Pharma, Inc.

• MEI Pharma Appoints Brian T. Powl As Senior Vice President, Marketing

  9/15/2020

  MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the appointment of Brian T. Powl as senior vice president, marketing, a new role that will report to David Urso, chief operating officer and general counsel, effective immediately.

• MEI Pharma Reports Fiscal Year 2020 Results and Operational Highlights

  9/9/2020

  MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year ended June 30, 2020. 

• MEI Pharma to Present at Upcoming Investor Conferences in September

  9/4/2020

  MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the following upcoming virtual investor conferences: Wells Fargo 2020 Virtual Healthcare Conference on Thursday, September 10, 2020 at 2:40 p.m. ET H.C. Wainwright

• MEI Pharma to Release 2020 Fiscal Year End Financial Results and Provide Corporate Update on September 9, 2020

  9/2/2020

  MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2020 fiscal year end financial results after the close of the U.S. financial markets on September 9, 2020. The Company will host a conference call and live webcast wi

• MEI Pharma to Present at the BTIG Virtual Biotechnology Conference 2020

  8/4/2020

  MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold, Ph.D., president and chief executive officer of MEI, will present a company overview and business update at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11 th ,

• 

  Clinical Catch-Up: June 29-July 3

  7/6/2020

  Heading into the 4th of July holiday in the U.S., there was still a fair amount of clinical trial news last week. Here’s a look.
• 

  Helsinn and MEI Discontinue Phase III Trial of Pracinostat in AML

  7/2/2020

  The decision was made after an interim futility analysis by an Independent Data Monitoring Committee determined the trial was unlikely to meet the primary endpoint of overall survival (OS) compared to the control group.

• MEI Pharma to Present at the Jefferies 2020 Virtual Healthcare Conference

  5/27/2020

  MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced that Daniel P. Gold, Ph.D., president and chief executive officer of MEI, will present a company overview and business update at the Jefferies Virtual Healthcare Conference on Tuesday, June 2nd, 2020 at 11:00 AM Eastern Time.

• MEI Pharma to Host Investor and Analyst Video Webcast Following ASCO20 Virtual Scientific Program

  5/26/2020

  MEI Pharma, Inc. announced that it will host an investor and analyst video webcast event on Tuesday, June 2nd, 2020 at 8:00 AM ET following the ASCO20 Virtual Scientific Program.

• MEI Pharma and Kyowa Kirin Announces ME-401 Phase 1b Study to be Highlighted in a Presentation at the Virtual Edition of the 25th European Hematology Association Annual Congress

  5/14/2020

  MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest biotechnology, today announced that updated Phase 1b data on ME-401, its investigational oral phosphatidylinositol 3-kinase delta

• MEI Pharma and Kyowa Kirin Announce Updated Clinical Data from the Phase 1b Study Evaluating ME-401 on an Intermittent Schedule in Patients with Follicular Lymphoma and Other B-cell Malignancies;

  5/13/2020

  Data to be Featured in the American Society of Clinical Oncology 2020 Virtual Scientific Program

• Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine in Patients with High/Very-high Risk Myelodysplastic Syndromes

  5/13/2020

  Data to be Featured in the American Society of Clinical Oncology Annual 2020 Virtual Scientific Program on May 29, 2020 at 8:00 a.m. EDT

• MEI Pharma Reports Fiscal Third-Quarter 2020 Results and Recent Corporate Highlights

  5/7/2020

  -- ME-401 global alliance with Kyowa Kirin executed, $100M in upfront payment and MEI eligible to receive up to an additional $582.5M in milestones -- -- Fast Track designation granted by US FDA to ME-401 for treatment of adult patients with relapsed or refractory follicular lymphoma --

• 

  BioSpace Movers & Shakers, April 17

  4/17/2020

  Pharma and life sciences companies boost their executive ranks and boards with this week's Movers & Shakers.

• MEI Pharma Appoints Cheryl Cohen, Product Launch and Commercialization Veteran, to its Board of Directors

  4/14/2020

  MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announced the appointment of Cheryl L. Cohen to its board of directors.

• MEI Pharma and Kyowa Kirin Announce Global License, Development and Commercialization Agreement for ME-401

  4/14/2020

  MEI Pharma and Kyowa Kirin will co-develop and co-promote ME-401 in the U.S.; MEI to book U.S. sales on 50-50 profit and cost sharing

• MEI Pharma to Present at the 19th Annual Needham Virtual Healthcare Conference

  4/8/2020

  MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold , Ph.D., president and chief executive officer, will present an overview and business update at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14 th  at 2:50 P

• MEI Pharma Announces Fast Track Designation Granted by U.S. FDA for ME-401 For the Treatment of Adult Patients with Relapsed or Refractory Follicular Lymphoma

  3/31/2020

  MEI Pharma, Inc. announced that the U.S. Food and Drug Administration granted Fast Track designation to ME-401, MEI's investigational selective oral inhibitor of phosphatidylinositol 3-kinase delta for the treatment of adult Patients with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.

• MEI Pharma Reports Fiscal Second-Quarter 2020 Results and Operational Highlights

  2/6/2020

  High Response Rate, Durability of Response and Tolerability of ME-401 Drives Decision to Consolidate Enrollment to Intermittent Dosing Schedule in the TIDAL Study Intended to Support an Accelerated Approval Marketing Application

• MEI Pharma Announces Closing of Public Offering of Common Stock

  12/19/2019

  MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced today that it has closed the underwritten public offering of 32,343,750 shares of its common stock, including 4,218,750 shares sold as a result of the exercise by the underwriters of their option to purchase additional shares,